immatics biotechnologies GmbH (4A3) — Financial Flexibility Index

Latest as of June 2026: -0.69x

immatics biotechnologies GmbH (4A3) has a Financial Flexibility Index of -0.69x as of June 2026. Free cash flow of €-59.59 Million (operating CF €-60.46 Million minus capex €871.00K) represents -1% of total liabilities (€86.11 Million). Check 4A3 capex plus investments ratio to assess the company's total reinvestment commitment from operating cash flow.

Financial Flexibility Index

-0.69x
Free Cash Flow / Total Liabilities

Free Cash Flow

€-59.59 Million
Operating CF − Capex

Total Liabilities

€86.11 Million
EUR

Capital Expenditures

€871.00K
EUR

immatics biotechnologies GmbH Financial Flexibility Index (2019–2025)

Historical Financial Flexibility Index trend for immatics biotechnologies GmbH across 7 annual periods. For the full cash flow conversion analysis, see how efficiently does immatics biotechnologies GmbH generate cash.

Annual Financial Flexibility Index for immatics biotechnologies GmbH (2019–2025)

Year-by-year free cash flow to debt coverage for immatics biotechnologies GmbH. Explore 4A3 operating cash to total liabilities to assess how comfortably operating cash covers total debt obligations.

Year Flexibility Index Free Cash Flow (EUR) Operating CF Total Liabilities YoY Change
2025 -2.17x €-169.82 Million €-176.63 Million €78.24 Million ▼ -86.0%
2024 -1.17x €-141.55 Million €-158.03 Million €121.30 Million ▼ -775.9%
2023 0.17x €49.19 Million €18.23 Million €284.88 Million ▼ -68.3%
2022 0.54x €105.87 Million €100.13 Million €194.66 Million ▼ -22.2%
2021 0.70x €105.24 Million €100.13 Million €150.58 Million ▼ -2.3%
2020 0.72x €107.55 Million €100.13 Million €150.39 Million ▲ +71.3%
2019 0.42x €73.11 Million €70.97 Million €175.11 Million
Financial Flexibility Index = (Operating CF − Capex) / Total Liabilities = Free Cash Flow / Total Liabilities